0

540729

VANTABIO

img img img img
No Data Available

Vanta Bioscience Limited Share Price Update

As of the latest trading session, Vanta Bioscience Limited is trading at ₹15.58, down by ₹-2.92 or -15.78% from its previous close. The stock has moved between ₹15.58 and ₹18.50 today. Over the past year, the stock has delivered a return of -14.86%. In the last month, it has returned 21.71%.

Investment Returns

Over 1 Month 21.71% Over 3 Months -6.98% Over 6 Months -33.18% Over 1 Year -14.86%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Vanta Bioscience Limited fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 11.10
  • P/E Ratio (TTM) -4.95
  • Beta 1.64
  • Book Value / share 29.71
  • Return on equity 0.00%
  • EPS (TTM) 0.00
  • Dividend yield [-]%
  • Net profit/quarter (Cr) -1.22
info icon alternate text

Vanta Bioscience Limited Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2023 (Values in Cr)
Revenue 1.76
Operating Expense 0.00
Net Profit -1.22
Net Profit Margin (%) -69.31
Earnings Per Share (EPS) 0.00
EBITDA 0.00
Effective Tax Rate (%) 0.00
Particulars DEC 2022 (Values in Cr)
Revenue 1.71
Operating Expense 3.21
Net Profit -1.51
Net Profit Margin (%) -88.30
Earnings Per Share (EPS) -2.39
EBITDA 0.32
Effective Tax Rate (%) -0.67
Particulars DEC 2021 (Values in Cr)
Revenue 0.00
Operating Expense 0.00
Net Profit 0.00
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.00
EBITDA 0.00
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 1.13
Operating Expense 3.88
Net Profit -2.66
Net Profit Margin (%) -235.39
Earnings Per Share (EPS) -4.21
EBITDA -1.62
Effective Tax Rate (%) 2.20
Particulars MAR 2024 (Values in Cr)
Revenue 8.56
Operating Expense 8.55
Net Profit 0.05
Net Profit Margin (%) 0.58
Earnings Per Share (EPS) 0.08
EBITDA 3.70
Effective Tax Rate (%) -25.00
Particulars MAR 2023 (Values in Cr)
Revenue 5.17
Operating Expense 10.01
Net Profit -4.24
Net Profit Margin (%) -82.01
Earnings Per Share (EPS) -6.71
EBITDA 0.14
Effective Tax Rate (%) -0.71
Particulars MAR 2022 (Values in Cr)
Revenue 9.35
Operating Expense 9.37
Net Profit 0.08
Net Profit Margin (%) 0.85
Earnings Per Share (EPS) 0.12
EBITDA 3.57
Effective Tax Rate (%) 42.85
Particulars MAR 2021 (Values in Cr)
Revenue 10.04
Operating Expense 9.46
Net Profit 0.47
Net Profit Margin (%) 4.68
Earnings Per Share (EPS) 0.75
EBITDA 3.92
Effective Tax Rate (%) 21.31
Particulars MAR 2025 (Values in Cr)
Book Value / Share 16.51
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 5.11
EBITDA Margin -211.22
Particulars MAR 2024 (Values in Cr)
Book Value / Share 24.08
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 3.61
EBITDA Margin 14.61
Particulars MAR 2023 (Values in Cr)
Book Value / Share 27.75
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 2.46
EBITDA Margin -27.07
Particulars MAR 2022 (Values in Cr)
Book Value / Share 38.03
ROE % 0.54
ROCE % 3.99
Total Debt to Total Equity 1.69
EBITDA Margin 40.14
Particulars MAR 2021 (Values in Cr)
Book Value / Share 37.89
ROE % 1.90
ROCE % 5.42
Total Debt to Total Equity 1.13
EBITDA Margin 39.64
Particulars MAR 2025 (Values in Cr)
Book Value / Share 27.14
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.51
EBITDA Margin -143.36
Particulars MAR 2024 (Values in Cr)
Book Value / Share 31.36
ROE % 0.05
ROCE % 5.24
Total Debt to Total Equity 1.29
EBITDA Margin 42.76
Particulars MAR 2023 (Values in Cr)
Book Value / Share 31.28
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.06
EBITDA Margin 2.90
Particulars MAR 2022 (Values in Cr)
Book Value / Share 38.01
ROE % 0.33
ROCE % 5.24
Total Debt to Total Equity 0.79
EBITDA Margin 38.18
Particulars MAR 2021 (Values in Cr)
Book Value / Share 37.88
ROE % 1.99
ROCE % 6.75
Total Debt to Total Equity 0.66
EBITDA Margin 39.04
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.22
Total Assets 85.87
Total Liabilities 85.87
Total Equity 3.78
Share Outstanding 0
Price to Book Ratio 0.82
Return on Assets (%) -5.55
Return on Capital (%) -6.46
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.16
Total Assets 85.39
Total Liabilities 85.39
Total Equity 12.97
Share Outstanding 0
Price to Book Ratio 2.04
Return on Assets (%) -2.71
Return on Capital (%) -3.13
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 84.70
Total Liabilities 84.70
Total Equity 18.92
Share Outstanding 0
Price to Book Ratio 1.84
Return on Assets (%) -7.65
Return on Capital (%) -8.52
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.22
Total Assets 81.40
Total Liabilities 81.40
Total Equity 29.34
Share Outstanding 0
Price to Book Ratio 2.89
Return on Assets (%) 0.10
Return on Capital (%) 0.13
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2.65
Total Assets 69.62
Total Liabilities 69.62
Total Equity 26.22
Share Outstanding 0
Price to Book Ratio 4.30
Return on Assets (%) 0.64
Return on Capital (%) 0.77
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.14
Total Assets 55.83
Total Liabilities 55.83
Total Equity 17.13
Share Outstanding 0
Price to Book Ratio 0.82
Return on Assets (%) -4.76
Return on Capital (%) -5.59
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.14
Total Assets 52.90
Total Liabilities 52.90
Total Equity 19.79
Share Outstanding 0
Price to Book Ratio 2.04
Return on Assets (%) 0.09
Return on Capital (%) 0.11
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.06
Total Assets 51.63
Total Liabilities 51.63
Total Equity 19.74
Share Outstanding 0
Price to Book Ratio 1.84
Return on Assets (%) -8.20
Return on Capital (%) -9.31
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.06
Total Assets 50.39
Total Liabilities 50.39
Total Equity 23.98
Share Outstanding 0
Price to Book Ratio 2.89
Return on Assets (%) 0.15
Return on Capital (%) 0.18
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.06
Total Assets 46.24
Total Liabilities 46.24
Total Equity 23.91
Share Outstanding 0
Price to Book Ratio 4.30
Return on Assets (%) 1.01
Return on Capital (%) 1.14
Particulars MAR 2024 (Values in Cr)
Net Income -8.82
Cash from Operations 2.68
Cash from Investing -3.31
Cash from Financing 0.69
Net change in Cash 0.06
Free Cash Flow 6.08
Particulars MAR 2023 (Values in Cr)
Net Income -10.26
Cash from Operations -0.62
Cash from Investing -5.90
Cash from Financing 6.40
Net change in Cash -0.12
Free Cash Flow 28.06
Particulars MAR 2022 (Values in Cr)
Net Income 0.22
Cash from Operations 5.27
Cash from Investing -17.18
Cash from Financing 9.53
Net change in Cash -2.42
Free Cash Flow 5.61
Particulars MAR 2021 (Values in Cr)
Net Income 0.58
Cash from Operations 6.97
Cash from Investing -22.19
Cash from Financing 17.78
Net change in Cash 2.45
Free Cash Flow 7.82
Particulars MAR 2020 (Values in Cr)
Net Income 1.34
Cash from Operations 2.34
Cash from Investing -7.35
Cash from Financing 2.17
Net change in Cash -3.07
Free Cash Flow 2.68
Particulars MAR 2024 (Values in Cr)
Net Income 0.04
Cash from Operations 4.54
Cash from Investing -1.66
Cash from Financing -2.80
Net change in Cash 0.07
Free Cash Flow 4.55
Particulars MAR 2023 (Values in Cr)
Net Income -4.20
Cash from Operations 0.64
Cash from Investing -2.53
Cash from Financing 1.88
Net change in Cash 0.00
Free Cash Flow 3.17
Particulars MAR 2022 (Values in Cr)
Net Income 0.13
Cash from Operations 6.70
Cash from Investing -8.05
Cash from Financing 1.37
Net change in Cash 0.00
Free Cash Flow 14.75
Particulars MAR 2021 (Values in Cr)
Net Income 0.60
Cash from Operations 11.00
Cash from Investing -9.85
Cash from Financing -1.07
Net change in Cash -0.02
Free Cash Flow 11.88
Particulars MAR 2020 (Values in Cr)
Net Income 1.28
Cash from Operations 3.16
Cash from Investing -1.34
Cash from Financing -1.80
Net change in Cash -0.19
Free Cash Flow 3.51
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
APOLLO HOSPITALS ENTER. L 7837.85 62.04 12.40 112696.26 6680.00 8099.00
FORTIS MALAR HOSPITALS LIMITED 56.61 23.39 3.08 106.10 40.75 81.00
SHREE PACETRONIX LTD. 137.80 20.78 3.04 51.67 66.10 283.15
TRANSGENE BIOTEK LTD. 3.06 0.00 2.51 23.19 1.83 5.26
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
APOLLO HOSPITALS ENTER. L 7837.85 77.59 12.09 112696.26 6680.00 8099.00
[-] 0.0 0.0 0.0 0.0 0.0 0.0
CHENNAI MEENAKSHI MULTISPECIAL 38.05 0.00 -11.05 28.42 30.02 57.48
KOVAI MEDICAL CENTER & HOSPITA 5757.45 26.71 5.29 6298.65 5010.00 6725.00

Vanta Bioscience Limited shareholding pattern

Holding
27.19%
72.8%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

Vanta Bioscience Limited Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
15.58 -15.78 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 18.00
  • 26 Days 17.90
  • 10 Days 17.70
  • 50 Days 19.10
  • 12 Days 17.60
  • 100 Days 21.60
  • 20 Days 17.70
  • 200 Days 27.40
18.50 PIVOT
First Support 18.50 First Resistance 18.50 Second Support 18.50 Second Resistance 18.50 Third Support 18.50 Third Resistance 18.50
RSI 52.10 ADX 23.94 MACD -0.31 Williams % R 0.00 Commodity Channel Index (CCI) 101.18
Date 2026-04-24 Week 3000.00 Same Day 1500.00 Month 6000.00
1 Year 1.65 3 Year 0.79
Over 1 Month
21.71% down
Over 1 Year
-14.86% down
Over 3 Months
-6.98% down
Over 3 Years
-30.13% down
Over 6 Months
-33.18% down
Over 5 Years
-35.04% down

Vanta Bioscience Limited Corporate Actions

Top Gainers

Top Losers

Vanta Bioscience Limited Share Price

Vanta Bioscience Limited (VBS) was originally incorporated as a Private Limited Company on 29th April 2016 and was converted into a Public Limited Company with effect from 17th March 2017.

VBS is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, Company provide risk assessment services for evaluating the safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. It also provides expert services for determination of health based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers.

The Company is established as a center of excellence for GLP toxicology and safety assessment offering services in India and across the globe. One of the major services of VBS is conducting variety of in vitro (cell, tissue and organisms) and in vivo (animal) toxicology studies for its diverse clients as per various regulatory requirements from across the world. Toxicology is a branch of biology, chemistry, and pharmacology concerned with the study of the adverse effects of chemicals on living organisms. It also studies the harmful effects of chemical, biological and physical agents in biological systems that establish the extent of damage in living organisms.

The Company purchased preclinical CRO facility at Gummidipundi, Chennai from Kemin Industries South Asia Private Limited which was named as 'Vanta Bioscience' (a toxicology division and commenced commercial activities in April, 2017. VBS has state of the art facilities and infrastructure necessary for conduct of all kind of toxicology studies for Chemicals, Pharmaceuticals, Cosmetics, Agrochemicals like Pesticides, Insecticides, Excipients, Novel Feed Additives.

In addition, the Company conducts preclinical proof-of-concept (PoC) studies for novel pharmaceuticals and products intended for new indications in variety of animal models of human diseases through a robust process of validation.

In September 2017, the Company came up with a Public Issue of 15,12,000 Equity Shares by raising money from public aggregating to Rs 7.56 Crore.

In 2018-19, Vanta Clinical Research Limited and Vayam Research Solutions Limited became the subsidiaries of the Company.

Parent organization Indian Private
NSE symbol [-]
Founded 2016
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Vanta Bioscience Ltd?

Answer Field

Vanta Bioscience Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 15.58 as on May 08 2026 03:22 PM.

What is the Market Cap of Vanta Bioscience Ltd Share?

Answer Field

The market cap of Vanta Bioscience Ltd for NSE ₹ 0.00 & for BSE ₹ 11.10 as on May 08 2026 03:22 PM.

What is the 52 Week High and Low of Vanta Bioscience Ltd?

Answer Field

The 52 Week High and Low of Vanta Bioscience Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 31.33 and ₹ 14.71.

What is 1 year return for Vanta Bioscience Ltd?

Answer Field

The 1 year returns on the stock has been -14.86%.

What is the P/E Ratio of Vanta Bioscience Ltd Share?

Answer Field

As on May 08 2026 03:22 PM the price-to-earnings (PE) ratio for Vanta Bioscience Ltd share is -4.95.

What is the PB ratio of Vanta Bioscience Ltd Share?

Answer Field

As on May 08 2026 03:22 PM, the price-to-book (PB) ratio for Vanta Bioscience Ltd share is 29.71.

How to Buy Vanta Bioscience Ltd Share?

Answer Field

You can trade in Vanta Bioscience Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Vanta Bioscience Ltd Share on Bajaj Broking App?

Answer Field

To buy Vanta Bioscience Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Vanta Bioscience Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|